Hanmi Pharm. Co., Ltd.

Hanmi Holdings Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Id Biochem, Inc.

Hanmi Pahrm. Co., Ltd.

Hanmi Science Co., Ltd.

Gwan-Sun Lee

Young-Kil Chang

Gha-Seung Park

Nam-Du Kim

Se-Chang Kwon

Kwee-Hyun Suh

Chul-Hyun Park

Jae-Heon Lee

Mi-Ra Seong

Young-ho Moon

Kyung-Ik Lee

Cheol-Kyung Kim

Sung-Youb Jung

Sung-Min Bae

Jae-cheol Lee

Ki-Doo Choi

Gi-Jeong Kim

Hong-Sun Kim

Young-Min Kim

Sung Youb Jung

Dae Hae Song

Jin Sun Kim

Dae-Jin Kim

Jaeheon Lee

Ki-eun Kim

Jong-Soo Woo

Moonsub Lee

Kyoung-Ik Lee

Hoe-Chul Lee

Wan-Joo Kim

Ju-Cheol Lee

Tae-Suk Lee

Cheol-Kyeung Kim

Kum-Sin Jung

Jin Hwan Shin

Han-Kyeng Kim

Maeng-Sup Kim

Cha-Soon Kim

Young-Jin Ham

Hee-Seock Kim

Kwang-Ok Lee

Hyoung-Jun Pae

Pyeong-uk Park

Seong-Nyun Kim

Woo-Hyuk Choi

Hak-Sun Jang

Chang-Ki Lim

Cheol-Kyong Kim

Jae-Chul Lee

Moon-Sub Lee

Han-Kyong Kim

Keum-Shin Jung

Hoon Shin

Jay-Do Choi

Sang-Min Yun

Sang-Min Yoon

Jae-Chul Kyungwonyeonlip Ra-Dong 101 Lee

Gha-Seung Sinjeongmaeul 1-Danji 107-1003 Park

Cheol-Kyong Sinnamusil Sinmyeong Apt 634-1003 Kim

Pyeong-Uk Park

A method for preparing high-purity polyethyleneglycol-alkylenealdehydes and derivatives thereof is provided.

Method for preparing high-purity polyethyleneglycol aldehyde derivatives

A protein conjugate having a prolonged in vivo half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced in vivo stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response.

Physiologically active polypeptide conjugate having prolonged in vivo half-life

Disclosed is a method for the mass production of a monomeric or dimeric immunoglobulin Fc region, free of initial methionine residues, using a recombinant expression vector comprising a nucleotide sequence coding for a recombinant immunoglobulin Fc region comprising an immunoglobulin Fc region linked at the N-terminus thereof to an immunoglobulin Fc region via a peptide bond.

Method for the mass production of immunoglobulin Fc region deleted initial methionine residues

A modified human granulocyte-colony stimulating factor (hG-CSF) is produced by culturing a microorganism transformed with an expression vector comprising a gene encoding a modified hG-CSF to produce and secrete the modified hG-CSF to periplasm, said modified hG-CSF being obtained by replacing at least one of the 1st, 2nd, 3rd and 17th amino acids of wild-type hG-CSF (SEQ ID NO: 2) with other amino acid.

Modified human granulocyte-colony stimulating factor and process for producing same

3R-carboxylate enantiomer derivative of formula (III) can be prepared easily and selectively by the method of the present invention, and a highly pure D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative can be prepared efficiently from the compound of formula (III) as an intermediate.

Method for the preparation of D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative

A clathrate of azithromycin hydrate with 1,2-propyleneglycol is much less hygroscopic than azithromycin hydrate or crystals known in the art, therefore, it can be useful for the preparation of a medicine for treating various microbial infections.

Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same

Risperidone is prepared in a high yield by reacting 2,4-difluorophenyl(4-piperidinyl)methanone oxime hydrochloride and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one in an aqueous alkali hydroxide solution having an alkali hydroxide concentration in the range of 20 to 40%.

Method for preparing risperidone

High purity cefdinir is prepared in a high yield by a process comprising the steps of: treating a crystalline salt of a cefdinir intermediate with a formic acid-sulfuric acid mixture or a formic acid-methanesulfonic acid mixture to obtain a crystalline salt of cefdinir and reacting the crystalline salt with a base in a solvent.

Crystalline acid salts of cefdinir and process for preparing cefdinir using same

A 3-(Z)-propenyl cephem compound is selectively prepared by reacting a phosphoranylidene cephem compound with acetaldehyde in the presence of a base in a solvent mixture comprising diethyl ether, formula (I), wherein R is a carboxyl protecting group; Ris hydrogen or RCHCO&#x2014;; and Ris ethyl, 2-thiophenyl, phenyl, p-hydroxyphenyl or phenoxy 

Process for the selective preparation of 3-(z) propenyl-cephem compound

This invention relates to a method for selectively preparing the 3-oxo-4-aza-5&#xa5;&#xe1;-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in the presence of zinc.

Method for the selective preparation of 3-oxo-4-aza-5&#x3b1;-androstane compound

Disclosed in this invention are an expression vector for the secretive production of human interferon alpha (hIFN&#x3b1;) comprising a polynucleotide encoding a modifiedthermostable enterotoxin II signal sequence and a polynucleotide encoding hIFN&#x3b1; ligated to the 3'-end thereof; a microorganism transformed with the expression vector; and a process for secretively producing human interferon by culturing the microorganism, the process being capable of secreting a soluble form of active hIFN&#x3b1;, which does not contain an additional methionine residue at its N-terminal, into the periplasm of ancell.

Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same

Amlodipine camsylate of the present invention is a crystalline salt of amlodipine suitable for pharmaceutical formulation, which is prepared by using low toxic camphor sulfonic acid to meet required pharmaceutical properties for treating cardiovascular diseases.

Amlodipine camsylate and method for preparing thereof

The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising novel crystalline sibutramine methanesulfonate hemihydrate of formula (I). The crystalline sibutramine methanesulfonate hemihydrate according to the present invention has a much higher solubility in water, and enhanced stability under a high humidity/temperature condition, as compared with sibutramine hydrochloride monohydrate

Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate

Clarithromycin can be easily prepared by reacting erythromycin A N-oxide with a methylating agent to obtain 6-O-methylerythromycin A N-oxide; and treating 6-O-methylerythromycin A N-oxide obtained above with a reducing agent in a high yield.

Method of preparing clarithromycin

Highly pure cefpodoxime proxetil can be prepared by a simple process comprising the step of reacting a cefpodoxime salt with 1-iodoethylisopropylcarbonate in an organic solvent in the presence of a crown ether.

Method of preparing highly pure cefpodoxime proxetil

Growing community of inventors

Seoul, South Korea

Gwan-Sun Lee